IGC logo

IGCIGC Pharma Inc

$0.299
$0.013
(4.54%)
Today
Closed $0.299
$0.0002
(0.07%)
After Hours
Updated: 07:59 PM EDT
Mkt Cap$28.63M
Vol630,623.00
News
all
press releases
AKAN Stock Leaves Cannabis Peers In The Smoke With A Stunning 1,700% Rally In April — What’s Fueling The Run?
The company’s primary cannabis asset remains its Gabriola Island cultivation site in British Columbia, where it operates under a hemp license.
Stocktwits
News Placeholder
More News
News Placeholder
TLRY, CGC, ACB, MSOS Pare Early Gains After Marijuana Reclassification: Retail Says ‘Weed Industry Is Reborn’
The U.S. Department of Justice formally moved to reclassify state-licensed medical marijuana as a less dangerous drug, four months after President Donald Trump signed an executive order.
Stocktwits
News Placeholder
TLRY, CGC, IGC Stocks Light Up On Trump Pot Reclassification Hopes This Week
Axios reported on Wednesday, citing an administration official, that the Trump administration is slated to reclassify marijuana as soon as Wednesday.
Stocktwits
News Placeholder
electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of +1.45% and -0.18%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Merck KGaA (MKKGY) Lags Q4 Earnings Estimates
Merck KGaA (MKKGY) delivered earnings and revenue surprises of -40.43% and +0.69%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of 0.00% and -56.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of +31.58% and +0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>

Advertisement|Remove ads.